Drug Profile
Research programme: checkpoint receptor agonist antibody therapeutics - AnaptysBio
Alternative Names: Checkpoint receptor agonist antibodiesLatest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator AnaptysBio
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Checkpoint kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 20 Sep 2023 Preclinical development is ongoing for Autoimmune-disorders and Inflammation in USA (Parenteral) (AnaptysBio website, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)